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wo the Editor: Carcinoid tumors are rare, arising in 3 to 4 per 100,000
eople per year (1). These tumors derive from enterochromaffin cells,
articularly those located in the gastrointestinal tract and the bron-
hopulmonary system. At diagnosis, 20% to 30% of patients present
ith disseminated disease and consequent carcinoid syndrome, char-
cterized by cutaneous flushing, gastrointestinal hypermotility, bron-
hospasm, and hypotension (2). The syndrome is associated with
xcess release of vasoactive substances of which serotonin is the most
rominent. Valvular manifestations of the tumor typically consist of
eaflet thickening and retraction of the right-sided valves and may
ause severe valvular dysfunction requiring surgical correction. Herein
e report our surgical experience in patients with carcinoid heart
isease (CHD).
From 2001 through 2006, 10 patients underwent valvular surgery
or CHD. A medical chart review was conducted to retrospectively
ollect demographic data and perioperative variables. Follow-up
nformation was obtained through the patients’ records and echocar-
iography reports from reference physicians. The study protocol
as approved by our institutional review board. All patients under-
ent pre-operative evaluation including determination of urinary
-hydroxyindoleacetic acid (HIAA) levels and other biological mark-
rs. Valvular morphology and function were assessed by echocardiog-
aphy. Coronary angiography was also performed in all patients.
Pre-operatively, all patients were on octreotide (150 to 300 g
dministered subcutaneously every 6 h or 20 to 30 mg of long-acting
ctreotide monthly). Intraoperatively, a loading dose of octreotide (50
g/h) was started before anesthetic induction. During anesthetic
nduction, an additional bolus of 50 to 100g was given. The infusion
f octreotide was increased to a maximum dose of 300 g/h if
equired. Additionally, aprotinin was administered perioperatively in
atients with preserved renal function at a loading dose of 2,000,000
allikrein inhibitor units (KIU). Then, a maintenance dose of 500,000
IU was given until the surgical procedure was finished. Post-
atient Characteristics and Echocardiographic Findings
Table 1 Patient Characteristics and Echocardiographic Findings
Patient # Age/Gender Tumor Location 5-HIAA mg/24 h*
1 56/F Unknown 256
2 55/M Ileum 254
3 64/F Cecum 239
4 66/M Testicular 264
5 68/M Jejunum 229
6 42/M Ileum 258
7 53/F Cecum 241
8 73/M Ileum 217
9 60/F Unknown 267
10 49/M Ileum 223
Reference values 2 to 10 mg/24 h.
AV  aortic valve; HF  hepatic failure; HIAA  hydroxyindolacetic acid; HTN  systemic hypertension;
V  pulmonic valve; PVD  peripheral vascular disease; RF  renal failure; SRVD  severe right ventriperatively, all patients returned to their octreotide routine on post-
perative day (POD) 2.
Patient characteristics are summarized in Table 1. Mean age
as 59  9 (mean  SD) years. Pre-operative cardiac medications
ncluded diuretics (n  9) and angiotensin-converting enzyme
nhibitors (n  1). The mean urinary 5-HIAA level was 247  18
g/24 h. Mean serotonin, chromogranin A, and atrial natriuretic
actor blood levels were 844  248 ng/ml, 816  315 ng/ml, and
15  86 pg/ml, respectively.
Echocardiography revealed tricuspid valve restricted leaflet motion
uring diastole and systole in all patients (see panels A and B of the
over image from this issue of the Journal). Four patients had
ssociated tricuspid stenosis (mean diastolic tricuspid valve gradient
.3  1.1 mm Hg). Six patients presented with severe right ventric-
lar dysfunction. Intraoperative analysis confirmed leaflet thickening
nd retraction with severe subvalvular involvement (see panel C of the
over image from this issue of the Journal). Tricuspid leaflets were
xcised, and a bioprosthetic replacement was performed in all patients.
Combined pulmonary regurgitation and stenosis (average pul-
onary valve peak gradient 14.2  9.1 mm Hg) was noted by
chocardiography in 9 patients. Operative analysis corroborated
eavily thickened and immobile leaflets in the pulmonic position.
ubsequently, a bioprosthetic replacement was performed in all
ases. Six patients received an additional patch augmentation of
he right ventricular outflow to accommodate the prosthetic valve.
Pre-operative echocardiography also revealed associated mitral
alve dysfunction due to leaflet thickening and retraction in 3
atients. Mitral regurgitation was moderate to severe in all cases.
one of the patients presented with mitral stenosis. On operative
nalysis, 2 patients had moderate thickening and retraction of the
osterior leaflets, whereas the anterior leaflets had preserved
obility. The subvalvular apparatus was moderately thickened
ith chordal fusion. Therefore, several secondary chordae were
YHA
ctional
lass
Associated
Comorbidities LVEF (%)
Valve Involvement
TV PV MV AV
III — 65 () () — —
IV HTN, HF 55 () () — —
IV — 60 () () — —
III RF 40 () () — —
IV HTN, RF 55 () () — —
III — 65 () () () ()
III — 60 () () — —
III HF 70 () — — —
III HTN, HF, PVD 70 () () () —
III HTN 50 () () () —N
Fun
CLVEF  left ventricular ejection fraction; MV mitral valve; NYHA  New York Heart Association;
cular dysfunction; TV  tricuspid valve.
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April 15, 2008:1507–11esected to increase the mobility of the posterior leaflet, and a
emodeling annuloplasty was performed in both patients. The
hird patient underwent a bioprosthetic valve replacement for
dvanced lesions. Only 1 patient presented with additional mod-
rate aortic valve regurgitation on pre-operative echocardiography.
n this case, operative analysis showed localized moderate thick-
ning of the right coronary cusp at the commissural area that was
urgically treated with a comissuroplasty. A patent foramen ovale
PFO) closure was concomitantly performed in 3 patients (1 of 3
ad left-sided valve involvement). Surgical details are summarized
n Table 2.
After valve replacement, valvular samples were processed and
tained with hematoxylin-eosin and Masson’s trichrome stain.
icroscopically, the presence of fibrocellular plaques with hyper-
ellularity and collagenous matrix was observed in all specimens
see panel D of the cover image from this issue of the Journal ).
Surgical outcome is detailed in Table 2. There were 2 (20%)
perative deaths. One patient developed low cardiac output syn-
rome due to right heart failure and subsequent multiorgan system
ailure and expired on POD 17. The second patient presented with
evere post-operative hypotension due to vasoplegia and developed
epato-renal syndrome. He expired on POD 10. The median
ength of hospital stay was 11 days (interquartile range 7 to 14
ays).
All 8 discharged patients were alive at a mean follow-up of 37
onths (range 6 to 75). There were no cases of endocarditis,
hromboembolic events, or structural valve deterioration. Five
atients were in New York Heart Association functional class I
nd 3 patients were in class II (Fig. 1). Patients’ medications
ncluded beta-blockers (n  5), diuretics (n  5), angiotensin-
onverting enzyme inhibitors (n 2), and calcium-channel inhibitors
n  1). All patients were on octreotide (30 to 60 mg monthly,
 6; 1,000 g daily, n  2). Echocardiographic findings at
ollow-up are reported in Table 2.
Advances in medical and oncologic therapies have resulted in
etter control of carcinoid symptoms and potentially improved
urvival. Consequently, right-sided valvular disease has become a
ajor source of morbidity and mortality. In 1995, Robiolio et al.
3) published a series of patients undergoing right-sided valve
eplacement with an operative mortality as high as 63%. More
ecently, Møller et al. (4) updated the Mayo Clinic experience and
howed that despite high post-operative mortality (16%), a trend
perative Procedures and Outcome
Table 2 Operative Procedures and Outcome
Patient #
Surgical Procedure
PFO
Closure
Major
Complications
L
(DTV PV MV AV
1 R R — — — —
2 R R — —  —
3 R R — — — —
4 R R — — — DIC, MSOF
5 R R — — — RSF
6 R R P P — —
7 R R — — — —
8 R — — —  Rectorragia
9 R R P — — HITT, MSOF
10 R R R —  —
R aortic regurgitation; DIC disseminated intravascular coagulation; EF ejection fraction; HI
rgan failure; MV  mitral valve; P  repair; PFO  patent foramen ovale; PR  pulmonic regurg
n Table 1.oward improved surgical outcome was achieved. In our series, weeport 2 (20%) operative deaths, both of which highlight the chal-
enges (vasoplegia and right heart failure) associated with cardiac
urgery in this patient population.
Others have reported perioperative coagulopathy as a major
ource of mortality and morbidity (5). This complication, mostly
resent in elderly patients with an abnormal liver profile, was not
bserved in our series. We believe that the reduction of post-
perative bleeding we observed may have been, in part, related to
he use of perioperative aprotinin in these patients.
In patients with right-sided CHD, valvular lesions are often too
dvanced and not amenable to reconstructive surgery. Although
he choice of valve prostheses remains unresolved and may require
ndividual selection, limited data suggest that bioprosthetic valve
eplacement is preferable in these patients, who commonly present
ith multiple liver metastases and associated coagulopathies (6).
urthermore, mechanical prostheses may not be ideal for
atients with CHD, as subsequent surgical tumor resections are
Figure 1 PreOp and Follow-Up NYHA Functional Class
for Patients Who Survive to the Surgical Procedure
NYHA  New York Heart Association; PreOp  pre-operative.
Discharge
Status
Patient Follow-Up
Follow-Up Echocardiography
Status
(Months) EF (%) TR PR MR AR
Alive Alive (75) 68 Mild Mild — —
Alive Alive (60) 55 None Trace — —
Alive Alive (50) 55 Mild Mod — —
Death — — — — — —
Alive Alive (34) 55 Mild Mild — —
Alive Alive (21) 50 Mod Mod Mild Mild
Alive Alive (23) 55 Mild Trace — —
Alive Alive (19) 65 Mod — — —
Death — — — — — —
Alive Alive (6) 53 None Trace Mild —
parin-induced thrombocytopenia; LOS length of stay; Modmoderate; MSOFmultisystemic
R  replacement; RSF  respiratory failure; TR  tricuspid regurgitation; other abbreviations asOS
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1509JACC Vol. 51, No. 15, 2008 Correspondence
April 15, 2008:1507–11ften required and are complicated by the use of anticoagula-
ion. Accordingly, all patients in this series underwent pericar-
ial bioprosthetic valve replacement in the tricuspid and pul-
onic positions.
Involvement of left-sided valves is rare and has been associated
ith the presence of an intracardiac shunt, endobronchial tumor
ocalization, or a high tumor activity. Connolly et al. (7), in the
nly published series specifically focused on left-sided CHD, noted
he absence of a PFO in 6 of 11 patients. Among these patients,
he authors reported higher levels of 5-HIAA. We observed a
FO in one-third of patients with left-sided valve involvement.
nterestingly, both patients without a PFO presented with the
ighest urinary 5-HIAA levels, potentially suggesting major tumor
ctivity. In contrast to right-sided CHD, the optimal surgical
pproach for left-sided valvular disease remains debatable. Our
xperience suggests that left-sided lesions may be less advanced
ompared with those on the right side. In these patients with
oderate left-sided valvular lesions, we elected to perform recon-
tructive surgery. Late echocardiography has shown only mild valvular
egurgitation, indicating that in selected cases these techniques can be
erformed safely with good midterm results.
avier G. Castillo, MD
arzan Filsoufi, MD
arwis B. Rahmanian, MD
nelechi Anyanwu, MD
erome S. Zacks, MD
anagement of systemic amyloidosis.
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9mTc-DPD Scintigraphy
n Cardiac Amyloidosis
n their useful state-of-the-art paper on the evaluation and manage-
ent of cardiac amyloidosis, Selvanayagam et al. (1) rightly dedicate
uch space to noninvasive evaluation but make no mention of
relevant imaging tool: 99mTc-3,3-diphosphono-1,2-propano-
icarboxylic acid (99mTc-DPD) scintigraphy. The authors do discuss
adiolabeled serum amyloid P component (SAP) scintigraphy, which
an provide valuable information on the distribution and extent of
myloid deposition in the body as a whole, but (as the authors point
ut) cannot adequately image amyloid in the heart. Unlike the SAP
echnique, 99mTc-DPD scintigraphy is capable of imaging amyloid
eposition in the myocardium of patients with transthyretin-related
TTR) amyloidosis (i.e., hereditary systemic amyloidosis and senile
ystemic amyloidosis) (2–5). This specific imaging characteristic may
acilitate differential diagnosis between TTR and AL cardiac amy-
oidosis in routine practice—a clinically relevant distinction (5).
ecause 99mTc-DPD scintigraphy is a standardized technique that
ses a widely available tracer, we think that this noninvasive exami-
ation should be known to all clinicians involved in the diagnosis andClaudio Rapezzi, MD
ierluigi Guidalotti, MD
abrizio Salvi, MD
etizia Riva, MD
nrica Perugini, MD, PhD
Istituto di Cardiologia
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